Newamsterdam Pharma Stock Investor Sentiment

NAMSW Stock   12.25  0.43  3.39%   
Slightly above 62% of NewAmsterdam Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding NewAmsterdam Pharma suggests that many traders are alarmed. NewAmsterdam Pharma's investing sentiment can be driven by a variety of factors including economic data, NewAmsterdam Pharma's earnings reports, geopolitical events, and overall market trends.
  

NewAmsterdam Pharma Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards NewAmsterdam Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a month ago at gurufocus.com         
NewAmsterdam Pharma to Present at Guggenheims SMID Cap Biotech Conference
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
NewAmsterdam Pharma Stock Price Down 4.9 percent - Should You Sell - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
NewAmsterdam Pharma Company N.V. Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
Google News at Macroaxis
over two months ago at gurufocus.com         
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
Gurufocus Stories at Macroaxis
over two months ago at gurufocus.com         
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
over two months ago at news.google.com         
NewAmsterdam Pharma Reaches New 1-Year High - Whats Next - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Obicetrapibs data positions NewAmsterdam Pharma stock for growth, says H.C. Wainwright - Investing.c...
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Smither John W of 10000 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3
Macroaxis News
over two months ago at news.google.com         
Newamsterdam Pharma sees 4.07 million in stock sales by Forbion funds - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
NewAmsterdam Pharma Trading Up 4.7 percent - Heres What Happened - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
NewAmsterdam Pharma Secures Massive 479M in Upsized Public Offering, Strengthens Financial Position ...
Google News at Macroaxis
over three months ago at gurufocus.com         
NewAmsterdam Pharma Announces Pricing of Upsized 416. ...
Gurufocus Stories at Macroaxis
over three months ago at thelincolnianonline.com         
NewAmsterdam Pharma Short Interest Down 71.4 percent in November
news
over three months ago at news.google.com         
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating - Yahoo Voices
Google News at Macroaxis
over three months ago at gurufocus.com         
NewAmsterdam Pharma Announces Commencement of 300 Million Public Offering of Ordinary Shares ...
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about NewAmsterdam Pharma that are available to investors today. That information is available publicly through NewAmsterdam media outlets and privately through word of mouth or via NewAmsterdam internal channels. However, regardless of the origin, that massive amount of NewAmsterdam data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NewAmsterdam Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NewAmsterdam Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NewAmsterdam Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NewAmsterdam Pharma alpha.

NewAmsterdam Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
NewAmsterdam Pharma Trading Up 4.7 percent - Heres What Happened - MarketBeat
12/17/2024
2
Acquisition by Smither John W of 10000 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3
12/27/2024
3
Obicetrapibs data positions NewAmsterdam Pharma stock for growth, says H.C. Wainwright - Investing.com
12/30/2024
4
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
01/10/2025
5
NewAmsterdam Pharma to Present at Guggenheims SMID Cap Biotech Conference
01/29/2025
6
NewAmsterdam Pharma Reaches 80-Plus Relative Strength Rating Benchmark - MSN
02/04/2025
7
Where are the Opportunities in - Stock Traders Daily
02/07/2025
8
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
02/25/2025
9
NewAmsterdam Pharma Company N.V. Yearly Results Heres What Analysts Are Forecasting For This Year - Yahoo Finance
02/28/2025
10
Stocks Showing Market Leadership NewAmsterdam Pharma Earns 92 RS Rating - Investors Business Daily
03/06/2025

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.